Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 131

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 131
---
 action has been taken to amend or supersede such determinations, resolutions, or authorizations; and |

| (ii) | the press release to be issued by the Purchaser announcing the Contemplated Transactions may so state and that 
 references to such support may be made in the Circular and other documents relating to the Arrangement.        |

E-17

SIGNING VERSION

SCHEDULE F

FORM OF CVR AGREEMENT

This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●] (this “Agreement”), is
entered into by and between Xeno Acquisition Corp. (the “Purchaser”), a Delaware corporation and a wholly owned Subsidiary of XenoTherapeutics Inc (the “Parent”), BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, a Pennsylvania limited liability company, as Rights Agent (as defined herein), and [●], solely in its capacity as the initial representative, agent and attorney in-fact of the Holders
(the “Representative”).

RECITALS

WHEREAS, Parent, Purchaser and Repare Therapeutics Inc., a corporation incorporated under the Business Corporations Act (Québec),
organized and existing under the laws of Canada and having its principal office at 7171 Frederick-Banting, Building 2, Suite 270, St-Laurent, Quebec, H4S 2A1, Canada (the “Company”),
have entered into an Arrangement Agreement, dated as of November 14, 2025 (the “Arrangement Agreement”), pursuant to which Parent, Purchaser and the Company will consummate the transactions described therein (the
“Transactions”);

WHEREAS, pursuant to the Arrangement Agreement, and in accordance with the terms and
conditions thereof, Purchaser shall deliver to holders of outstanding Common Shares, Options and RSUs (subject to certain exceptions) certain CVRs (collectively, the “Initial Holders”), pursuant to the terms and subject to
the conditions hereinafter described;

WHEREAS, the CVRs are a part of the consideration to be received by the Initial Holders in the
Arrangement;

WHEREAS, Purchaser desires that the Rights Agent act as its agent for the purposes of effecting the distribution of the CVRs
to the Initial Holders and performing the other services described in this Agreement; and

WHEREAS, the Company has designated the
Representative to act as agent for the Initial Holders for the purposes of accomplishing the intent and implementing the provisions